Re: Farmas USA
Desde hace unos dias no puedo leer bien el foro desde el ordenador (desde el movil no me pasa) le pasa a alguien mas? puedo hacer algo para cambiar el formato?
Tengo 3 biotech medianas para empezar a seguir por posible interés de inversión,al precio adecuado. todas tienen catalysts cercanos. las sigue alguien?:
1- Intra-Cellular Therapies is developing the lead molecule ITI-007 for the treatment of schizophrenia, bipolar disorder and behavioral disturbances in dementia. ITI-007 is an improved 5-HT2A serotonin receptor antagonist, designed to offer similar efficacy but improved tolerability profile compared to established drugs of the same class. The company has announced one positive Phase 3 study for schizophrenia, and a second Phase III trial is expected to readout in the third quarter of 2016.
2- Macrogenics is an antibody technology company developing effector function improved antibodies and a novel platform called DART (Dual-Affinity-Re-Targeting) which offers potential for the efficient development of bispecific antibodies. This platform has been partially validated through multiple partnerships with major pharma companies.
3-Tobira Therapeutics is developing Cenicriviroc, a dual CCR2 and CCR5 antagonist for treating patients with nonalcoholic steatohepatitis or NASH – a common, often “silent” liver disease. The company has a large Phase II study ongoing with data readout expected later in 2016